Home Link

FierceBiotech Radio

FierceBiotech brings you interviews and analysis from around the biotech, pharma and medical device industries.

All shows

Sort by
Pricing drugs, selling hype and how we got here in the first place
FierceBiotech Radio
Pricing drugs, selling hype and how we got here in the first place

drug

capitalism

fraud

venture

biotech

+4
+4
+3
+3
+2
+2

drug

capitalism

fraud

venture

biotech

+4
+4
+3
+3
+2
+2
The FierceMadness drug name showdown and how do drugs get their zany names anyway?
FierceBiotech Radio
The FierceMadness drug name showdown and how do drugs get their zany names anyway?

marketing

fda

branding

drug

pharma

+5
+4
+3
+3
+2
+2

marketing

fda

branding

drug

pharma

+5
+4
+3
+3
+2
+2
GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster
FierceBiotech Radio
GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster
The FDA's new boss, Sanofi's latest shortcut, and a little 'financial innovation'
FierceBiotech Radio
The FDA's new boss, Sanofi's latest shortcut, and a little 'financial innovation'
Pharma's TV blitz, biotech's IPO trickle, and the M&A future of Intercept Pharmaceuticals
FierceBiotech Radio
Pharma's TV blitz, biotech's IPO trickle, and the M&A future of Intercept Pharmaceuticals
Pharma's day on the Hill, biotech's paucity of M&A, and the gathering storm of biosimilars
FierceBiotech Radio
Pharma's day on the Hill, biotech's paucity of M&A, and the gathering storm of biosimilars
Gilead's wide-open future, biotech's long winter, and Sanofi's ongoing makeover
FierceBiotech Radio
Gilead's wide-open future, biotech's long winter, and Sanofi's ongoing makeover
Shire's byzantine Baxalta pursuit, biotech's pragmatic winter and Valeant's CEO shakeup
FierceBiotech Radio
Shire's byzantine Baxalta pursuit, biotech's pragmatic winter and Valeant's CEO shakeup
The burning hole in Gilead's $25B pocket and AbbVie's future in hematology
FierceBiotech Radio
The burning hole in Gilead's $25B pocket and AbbVie's future in hematology
Gilead's maxed-out revenue, BioMarin's FDA struggles, and GSK's rock and hard place
FierceBiotech Radio
Gilead's maxed-out revenue, BioMarin's FDA struggles, and GSK's rock and hard place